SELLAS Life Sciences Group, Inc.
Reports in 15d· 2026-05-12
+10.9% · 90d
$4.88
+0.42 (+9.42%)
After-Hours $4.96(+0.08)
News
(1)April 2026
SLS Highlights Pivotal Breast Cancer Trial in Annual Report
SLSSELLAS Life Sciences Group, Inc.
# 🧾 What This Document Is This is SELLAS Life Sciences Group's Annual Report to Shareholders (ARS). Think of it as the company's "yearbook" for investors. It's not just the financial numbers; it's a comprehensive look at their business, strategy, clinical trials, and the risks they face. It summari
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%